Hm Payson & CO Arvinas, Inc. Transaction History

Hm Payson & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$60.27 - $81.57 $5,785 - $7,830	-96 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$65.85 - $96.21 $6,321 - $9,236	96 New	96 $8,000
Q2 2021 Aug 17, 2021	SELL	$60.45 - $84.26 $11,606 - $16,177	-192 Closed	0 $0
Q4 2020 Mar 10, 2021	SELL	$20.19 - $84.93 $1,070 - $4,501	-53 Reduced 21.63%	192 $16,000
Q3 2020 Dec 21, 2020	BUY	$22.99 - $36.34 $5,632 - $8,903	245 New	245 $6,000

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

Stay updated on Hm Payson & CO with notifications on news.